Trials / Completed
CompletedNCT03019419
Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)
Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trials
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Tokyo Medical University · Academic / Other
- Sex
- All
- Age
- 40 Years – 78 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the safety and the efficacy of perampanel in patients with sporadic amyotrophic lateral sclerosis
Detailed description
To evaluate the effect of peramanel for 48 weeks on progression of disease in subjects with ALS, as measured by ALS Functional Rating Scale-Revised (ALSFRS-R)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Perampanel | 4mg/d or 8mg/d |
| DRUG | placebo | placebo |
Timeline
- Start date
- 2017-04-24
- Primary completion
- 2020-12-23
- Completion
- 2020-12-23
- First posted
- 2017-01-12
- Last updated
- 2021-01-15
Locations
12 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03019419. Inclusion in this directory is not an endorsement.